Get the Stockscreener App
130.98
0.99%
1.28
After Hours:
131.83
0.85
+0.65%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $130.98, with a volume of 10.46M.
It is up +0.99% in the last 24 hours and up +2.62% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$129.70
Open:
$130.375
24h Volume:
10.46M
Relative Volume:
1.47
Market Cap:
$221.92B
Revenue:
$41.95B
Net Income/Loss:
$13.40B
P/E Ratio:
17.12
EPS:
7.65
Net Cash Flow:
$6.35B
1W Performance:
+5.20%
1M Performance:
+2.62%
6M Performance:
+11.10%
1Y Performance:
+23.68%
1-Day Range:
$129.66
$132.71
1-Week Range:
$124.04
$134.16
52-Week Range:
$99.71
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
130.98 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.12 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.50 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.60 | 108.02B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Laboratories to invest $500M in manufacturing, add 200 jobs in Illinois - Chicago Sun-Times
Abbott expects a ‘few hundred million’ in tariff costs in 2025 - Manufacturing Dive
Abbott Laboratories (NYSE:ABT) Q1 2025 Earnings Call Transcript - MSN
Brazil Enteral Nutrition Market Overall Study Report 2025-2032 - openPR.com
Tariff-Resistant Abbott Laboratories on Track for New Highs - Investing.com
Tariff-Resistant Abbott Laboratories on Track for New Highs - Investing.com
Abbott Laboratories’ Earnings Call Highlights Robust Growth - TipRanks
Abbott Laboratories Plans $500M Manufacturing, R&D Expansion In DFW and Chicago - Bisnow
Abbott Laboratories Adjusts Financial Outlook With Increased Price Target - Evrim Ağacı
Abbott Laboratories First Quarter 2025 Earnings: EPS Misses Expectations - simplywall.st
RBC Capital lifts Abbott Labs target to $145, maintains Outperform By Investing.com - Investing.com India
Abbott Labs stock target raised to $144 by Bernstein SocGen - Investing.com India
RBC Capital lifts Abbott Labs target to $145, maintains Outperform - Investing.com
UBS maintains Buy on Abbott Labs with $148 price target By Investing.com - Investing.com India
Abbott price target raised to $140 from $138 at Evercore ISI - Yahoo Finance
Abbott Labs (ABT) Stock: Earnings Beat with Strong MedTech Growth and $500M U.S. Investment - CoinCentral
UBS maintains Buy on Abbott Labs with $148 price target - Investing.com
These Analysts Boost Their Forecasts On Abbott Laboratories After Better-Than-Expected Earnings - Benzinga
Piper Sandler raises Abbott Labs target to $145, keeps Overweight By Investing.com - Investing.com India
Piper Sandler raises Abbott Labs target to $145, keeps Overweight - Investing.com
Citi Reaffirms Their Buy Rating on Abbott Laboratories (ABT) - The Globe and Mail
Demystifying Abbott Laboratories: Insights From 11 Analyst Reviews - Benzinga
RBC Capital Increases Price Target for Abbott (ABT) to $145 | ABT Stock News - GuruFocus
Stifel cuts Abbott Labs stock target to $135, maintains buy rating - Investing.com India
Abbott Laboratories: Strong Performance and Strategic Positioning Drive Buy Rating - TipRanks
Oppenheimer Increases Price Target for Abbott (ABT) to $140 | ABT Stock News - GuruFocus
Abbott Laboratories (ABT): Among the Innovative Healthcare Stocks to Watch in 2025 - Yahoo Finance
Bernstein Boosts Abbott (ABT) Price Target to $144 on Strong Performance | ABT Stock News - GuruFocus
BTIG Ups Abbott (ABT) Price Target After Impressive Q1 Earnings | ABT Stock News - GuruFocus
Abbott Laboratories: Strong Growth and Resilience Justify Buy Rating - TipRanks
Oppenheimer lifts Abbott Labs target to $140, maintains outperform By Investing.com - Investing.com India
Oppenheimer lifts Abbott Labs target to $140, maintains outperform - Investing.com
BTIG raises Abbott Labs stock price target to $145 - Investing.com
Raymond James raises Abbott Labs price target to $142 - Investing.com
Raymond James raises Abbott Labs price target to $142 By Investing.com - Investing.com UK
Street View: Abbott's effective management could help it triumph over tariffs - TradingView
Abbott Laboratories (ABT) Q1 2025 Earnings Call Highlights: Strong Growth in Medical Devices ... - Yahoo Finance
Abbott Laboratories (ABT) Q1 2025 Earnings Call Highlights: Strong Growth in Medical Devices and Nutrition Amidst Diagnostics Challenges - GuruFocus
Abbott Laboratories Reports Strong Q1 2025 Results - TipRanks
Abbott to Expand US Manufacturing as Tariffs Loom - MSN
Abbott Laboratories: Strong Buy Rating Amid Robust Financial Performance and Growth Potential - TipRanks
Is Abbott a Beacon of Hope in the Tariff Conflict? - Medical Device and Diagnostic industry
Wintrust Business Minute: Abbott Laboratories to spend $500 million on manufacturing facilities, including one in Illinois - WGN Radio 720
Stocks Sink After Nvidia Warning: TG Therapeutics, Abbott Labs, Loar In Focus - Investor's Business Daily
Nvidia, AMD, ASML, United, Tesla, Abbott Labs, Travelers, Interactive Brokers, and More Movers - Barron's
Hertz, Abbott Laboratories, and Interactive Brokers: Trending tickers - Yahoo Finance
Health Giant Makes A Bullish Move Despite Mixed Report - Investor's Business Daily
Abbott Q1: Flexible Supply Chain And Strong Growth In Medical Devices (NYSE:ABT) - Seeking Alpha
Is Abbott Laboratories (ABT) the Best Dividend Monarch to Invest in Now? - Insider Monkey
Abbott to invest millions in Irving facility - The Business Journals
Healthcare Stocks Take A Hit Despite Abbott's Earnings Beat - Finimize
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):